Hematologic diseases: High risk of Clostridium difficile associated diarrhea

doi:10.3748/wjg.v20.i21.6602

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 21

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6113)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

339

WORD

208

HTML

3228

Tables (1-4)

213

Sum=3988

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1043

Download

1082

Sum=2125

Jun 7, 2014 (publication date) through Jan 29, 2025

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jun 7, 2014; 20(21): 6602-6607
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6602

Table 1 Demographic characteristics and risk factors for Clostidirium difficile associated diarrhea of the study subjects n (%)

Characteristics	HD(n = 144)	NHD(n = 176)	P value
Male	84 (58.3)	102 (58.0)	0.90
Age (mean ± SD)	47.4 ± 17.2	65.2 ± 16.0	< 0.01
Body mass index (mean ± SD), kg/m²	22.4 ± 3.4	20.4 ± 7.1	< 0.01
Charlson score	2.3 ± 1.0	4.0 ± 2.5	< 0.01
WBC (mean ± SD)/mm³	3093.6 ± 3879.1	9160.0 ± 6252.1	< 0.01
ANC (mean ± SD)/mm³	2014.7 ± 3052.4	6843.2 ± 5473.9	<0.01
Neutropenia	67 (46.5)	4 (2.3)	<0.01
Total hospital days within 60 d	22.2 ± 13.9	23.1 ± 17.0	0.62
Previous anti-cancer chemotherapy	139 (96.5)	60 (34.1)	< 0.01
Antibiotics
Use of antibiotics	142 (98.6)	166 (94.3)	0.07
Number of antibiotics	4.0 ± 1.6	2.6 ± 1.6	< 0.01
Days of antibiotics	27.8 ± 15.7	17.3 ± 13.9	< 0.01
Concomitant medications
Anti-fungal agents	111 (77.1)	21 (11.9)	< 0.01
Acyclovir, ganciclovir	44 (31.7)	7 (4.0)	< 0.01
Proton pump inhibitor	62 (43.1)	56 (31.8)	0.04
H2 antagonist	71 (51.1)	91 (45.3)	0.67
Toxin assay			0.30
Toxin A + B	111 (77.1)	132 (75.0)
Toxin B	26 (18.1)	40 (22.7)
Toxin A + B + binary toxin	7 (4.9)	4 (2.3)
Pseudomembranous colitis	7/31 (22.6)	16/32 (50)	0.02

CDAD: Clostidirium difficile associated diarrhea; HD: Hematologic disease; NHD: Nonhematologic disease.

Table 2 Antibiotic use of the study subjects n (%)

Antibiotics	HD(n =144)	NHD(n =176)	P value
Cephalosporin	128 (88.9)	119 (67.6)	< 0.01
Aminoglycoside	96 (66.7)	34 (19.3)	< 0.01
Quinolone	99 (68.9)	63 (35.8)	< 0.01
Carbapenem	58 (40.3)	39 (22.2)	< 0.01
Glycopeptide	43 (29.9)	47 (26.7)	0.53
β lactam/β lactamase inhibitor	40 (27.8)	82 (46.6)	< 0.01
TMP/SMX	30 (20.8)	9 (5.1)	< 0.01
Macrolide	16 (11.1)	19 (10.8)	0.93

HD: Hematologic disease; NHD: Nonhematologic disease; TMP/SMX, Trimethoprim/sulfamethoxazole.

Table 3 Treatment and clinical course of the study subjects n (%)

Characteristics	HD(n =144)	NHD(n =176)	P value
Treatment			0.82
Cessation of causative antibiotics for CDAD	42 (29.2)	57 (32.4)
Metronidazole	95 (66.0)	111 (63.1)
Oral vancomycin	7 (4.9)	8 (4.5)
Additional use of causative antibiotics for CDAD	109 (75.7)	79 (44.9)	< 0.01
Continuous use	67 (46.5)	22 (12.5)
Re-use	42 (29.2)	57 (32.4)
Concomitant use of IVIG	80 (55.6)	11 (6.3)	< 0.01
Severe CDAD	11 (7.6)	43 (24.4)	< 0.01
Leukocytosis	3 (2.1)	18 (10.2)	< 0.01
Hypoalbuminemia	5 (3.5)	31 (17.6)	< 0.01
AKI	3 (2.1)	11 (6.3)	0.10
Clinical outcome
Overall mortality within 1 mo	23 (16.0)	29 (16.5)	0.90
Mortality due to CDAD within 1 mo	1 (0.7)	1 (0.6)	0.89
Recurrence	27 (18.8)	15 (8.5)	< 0.01

HD: Hematologic disease; NHD: Nonhematologic disease; CDAD: CDAD: Clostidirium difficile associated diarrhea; IVIG: Intravenous immunoglobulin; AKI: Acute kidney injury.

Table 4 Comparison of recurrent vs non-recurrent Clostidirium difficile associated diarrhea in the hematologic disease group n (%)

Characteristics	Recurrent	Single episode	Univariate analysis	Multivariate analysis
	n =27	n =117	P value	P value	Odds ratio (95%CI)
Male	13 (48.1)	71 (60.7)	0.23
Age (mean ± SD)	47.5 ± 16.0	47.3 ± 17.6	0.93
Body mass index (mean ± SD), kg/m²	22.3 ± 3.6	22.4 ± 3.4	0.87
Total hospital days within 60 d	24.3 ± 12.9	21.8 ± 14.1	0.89
Charlson score	2.5 ± 1.7	2.2 ± 0.8	0.13
Antibiotics
Use of antibiotics	27 (100)	115 (98.3)	0.49
Number of antibiotics	4.2 ± 1.4	4.0 ± 1.7	0.57
Duration of antibiotics	27.8 ± 13.3	27.8 ± 16.2	1.0
WBC (mean ± SD)/mm³	1326.7 ± 1813.7	3501.4 ± 4113.1	< 0.01	0.50	1.0 (0.998-1.003)
ANC (mean ± SD)/mm³	751.1 ± 1224.5	2306.2 ± 3269.9	0.02	0.83	1.0 (0.997-1.002)
Neutropenia	17 (63.0)	50 (42.7)	0.04	0.87	1.13 (0.37-4.74)
Severe CDAD	2 (7.4)	9 (7.7)	1.0
Toxin assay
Toxin A + B	26 (96.2)	85 (72.6)	< 0.01	0.87	0.82 (0.8-8.8)
Toxin B	0 (0.0)	26 (22.2)	< 0.01	1.00	0
Toxin A + B + binary toxin	1 (3.7)	6 (5.1)	1.0
Treatment for CDAD			0.68
Metronidazole or vancomycin	20 (74.1)	82 (70.1)
Discontinuation of causative antibiotics	7 (25.9)	35 (29.9)
IVIG	8 (29.6)	72 (61.5)	< 0.01	< 0.01	0.24 (0.09-0.65)
Additional use of causative antibiotics for CDAD	27 (100.0)	82 (70.1)	< 0.01	1.00	0
Continuous use	20 (74.1)	47 (40.2)
Re-use	7 (25.9)	35 (29.9)

CDAD: Clostidirium difficile associated diarrhea; WBC: White blood cell; ANC: Absolute neutrophil count; IVIG: Intravenous immunoglobulin.

Citation: Gweon TG, Choi MG, Baeg MK, Lim CH, Park JM, Lee IS, Kim SW, Lee DG, Park YJ, Lee JW. Hematologic diseases: High risk of Clostridium difficile associated diarrhea. World J Gastroenterol 2014; 20(21): 6602-6607
URL: https://www.wjgnet.com/1007-9327/full/v20/i21/6602.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i21.6602